GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Gross Profit

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Gross Profit : $11.13 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Gross Profit?

Parnell Pharmaceuticals Holdings's gross profit for the six months ended in Dec. 2018 was $11.13 Mil. Parnell Pharmaceuticals Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2018 was $11.13 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Parnell Pharmaceuticals Holdings's gross profit for the six months ended in Dec. 2018 was $11.13 Mil. Parnell Pharmaceuticals Holdings's Revenue for the six months ended in Dec. 2018 was $19.03 Mil. Therefore, Parnell Pharmaceuticals Holdings's Gross Margin % for the quarter that ended in Dec. 2018 was 58.47%.

Parnell Pharmaceuticals Holdings had a gross margin of 58.47% for the quarter that ended in Dec. 2018 => Durable competitive advantage


Parnell Pharmaceuticals Holdings Gross Profit Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Gross Profit Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Gross Profit
Get a 7-Day Free Trial 3.16 8.80 7.40 7.17 11.13

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Gross Profit Get a 7-Day Free Trial 3.16 8.80 7.40 7.17 11.13

Competitive Comparison of Parnell Pharmaceuticals Holdings's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Gross Profit falls into.



Parnell Pharmaceuticals Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Parnell Pharmaceuticals Holdings's Gross Profit for the fiscal year that ended in Dec. 2018 is calculated as

Gross Profit (A: Dec. 2018 )=Revenue - Cost of Goods Sold
=19.031 - 7.903
=11.13

Parnell Pharmaceuticals Holdings's Gross Profit for the quarter that ended in Dec. 2018 is calculated as

Gross Profit (Q: Dec. 2018 )=Revenue - Cost of Goods Sold
=19.031 - 7.903
=11.13

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Dec. 2018 was $11.13 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Parnell Pharmaceuticals Holdings's Gross Margin % for the quarter that ended in Dec. 2018 is calculated as

Gross Margin % (Q: Dec. 2018 )=Gross Profit (Q: Dec. 2018 ) / Revenue (Q: Dec. 2018 )
=(Revenue - Cost of Goods Sold) / Revenue
=11.13 / 19.031
=58.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Parnell Pharmaceuticals Holdings had a gross margin of 58.47% for the quarter that ended in Dec. 2018 => Durable competitive advantage


Parnell Pharmaceuticals Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.